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Abstract 
Tumors  of  the  matrix  of  rigid  structures
include matrical tumors of the hairs, nails, and
teeth. These tumors share similar phenotyp  -
ical and signaling features. Although benign
matrical hair tumors are among the most com-
mon of these tumors, hair matrix tumors con-
taining pigmented melanocytes are very rare.
The malignant variant called melanocytic pilo-
matrix carcinoma contains benign colonizing
dendritic melanocytes admixed with the car  -
cinomatous follicular matrical cells. 
We studied the expression of cadherins and
b-catenin in melanocytic pilomatrix carcinoma
because  cadherin/catenin-dependent  cell-cell
adhesion and signals play a critical role in the
development of hair and hair tumors. We exam-
ined the expression of E- and P-cadherin and
the  multifunctional  protein  b-catenin  in  two
cases of melanocytic pilomatrix carcinoma by
immunohistochemistry. E- and P-cadherin are
expressed at the cell membrane. In contrast, b-
catenin is distributed uniformly in the nucleus
and cytoplasm of all tumor cells. The diffuse
nuclear and cytoplasmic b-catenin expression
found in melanocytic pilomatrix carcinomas is
indicative of transcriptional activation and b-
catenin-induced cell transformation. 
This is the first report of cadherin/catenin
expression in melanocytic pilomatrix carcin  -
oma. Although the study is limited by the num-
ber of these rare tumors, the data add informa-
tion for the understanding of disease mech  -
anisms  in  hair  matrical  tumors.  Matrical
tumors  of  the  hairs  share  phenotypical  fea-
tures  with  other  matrical  tumors  and  show
nuclear translocation of b-catenin, suggesting
a transcriptional activating rather than a cell-
cell adhesion function.
Introduction
Matrical tumors of rigid structures include
tumors  of  the  hair,  nail,  and  teeth  matrices.
Tumors of the hair matrix constitute a spectrum
of neoplasms that includes the common benign
pilomatricoma,
1,2 pigmented  matricoma,
3 and
the uncommon melanocytic matricoma, which
contain  colonizing  dendritic  melanocytes
admixed with the matrical epithelial cell.
4 The
malignant  variants  include  the  proliferating
pilomatricoma,
5 pilomatrix  carcinoma,
6 pig-
mented pilomatrix carcinoma,
7 and melanocytic
pilomatrix carcinoma.
8 Melanocytic pilomatrix
carcinoma  is  the  rarest  of  this  group  and  is
composed  of  highly  atypical  epithelial  matrix
cells exhibiting atypical mitoses admixed with
benign dendritic melanocytes.
9
Cadherins  are  a  large  family  of  calcium-
dependent  cell-cell  adhesion  proteins  linked
within the cytoplasm to a group of cytoskeletal
proteins  called  catenins.
10 Cadherin/catenin-
dependent cell-cell adhesion is involved in cell
sorting  and  tissue  morphogenesis.  The  best
characterized are the type I or classical cad-
herins, a group that includes E (epithelial)-, P
(placental)-, and N (nerve)-cadherin.
11 One of
the  catenins,  b-catenin,  is  a  multifunctional
protein with both cell-cell adhesion and signal-
ing  functions.  In  the  skin,  cadherin/catenin-
dependent cell-cell adhesion and signals play a
critical role in the development of hair and hair
tumors.
12-14 Here we report the expression of E-
cadherin,  P-cadherin,  and  b-catenin  in  two
cases of melanocytic pilomatrix carcinoma.
Materials and Methods
The patients were an 84-year-old Caucasian
male with a 0.5-cm left postauricular dark nod-
ule, clinically diagnosed as a basal cell carcin  -
oma, and an 83-year-old Caucasian male with a
6-month duration, dark nodule on the left mid-
back, approximately 0.6 cm in size. After rou-
tine  histological  evaluation,  immunohisto-
chemistry was done either manually or with
the  Ventana  (Tucson,  AZ)  and  Bond  Max
(Leica  Microsystems,  Bannockburn  IL,  USA)
automated  systems  using  alkaline  phos-
phatase and horseradish peroxidase detection
systems. Mouse monoclonal antibodies includ-
ed anti-E-cadherin, clone NCH-38 IgG1 (Dako,
Carpinteria  CA)  used  at  1:100;  anti-P-cad-
herin,  clone  56  IgG1  (BD  Biosciences,  San
Jose,  CA)  used  at  1:50,  and  anti-b-catenin,
clone b-catenin-1 IgG1 (Dako) used at 1:200.
Melanocytic markers included Melan-A mouse
monoclonal IgG1, (Dako) used at 1:100; HMB-
45  mouse  monoclonal  IgG1  (Dako)  used  at
1:100,  and  S-100  rabbit  polyclonal  antibody
(Dako, Carpinteria CA) used at 1:1200 without
antigen retrieval pretreatment. Four micron-
thick  sections  were  placed  on  positively
charged  slides  and  air  dried.  After  paraffin
removal and quenching of endogenous perox  -
idase,  sections  were  hydrated  and  heat-
induced epitope retrieval was performed. For
E-cadherin manual staining, 10 mM Tris and 1
mM EDTA pH 9.0 cocktail was used in a pres-
sure  cooker  for  5  min.  For  P-cadherin,  b-
catenin,  and  HMB-45  manual  staining,  1x
Target Retrieval citrate buffer solution pH 6.1
(Dako) was used for 20 min in a 100°C water
bath. For manual staining, after cooling and
rinsing,  primary  antibodies  diluted  in  1%
bovine albumin in TBS were incubated for 1 hr
at  room  temperature.  Mouse  IgG  (Southern
Biotech) or rabbit Ig (Dako) were used as neg-
ative  controls.  The  primary  antibodies  were
detected  with  alkaline  phosphatase  labeled
anti-rabbit  or  anti-mouse  detection  systems
(Biocare  Medical,  Concord  CA,  USA).  Color
end product was obtained with either Vulcan
Fast Red or 3,3’diaminobenzidine chromogens
(Biocare  Medical)  and  counterstaining  with
Harris hematoxylin. Automated staining was
done following the manufacturers’ programs.
Overlying epidermis in both cases served as
the internal positive control. Tissue sections
from a melanocytic lesion were used as a posi-
tive  control  for  the  melanocytic  markers.  A
block containing various carcinomas express-
ing E-cadherin, P-cadherin, and b-catenin was
used as an additional positive control.
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Routine hematoxylin and eosin sections of
both  cases  showed  a  relatively  well-circum-
scribed  but  not  encapsulated  dermal  tumor
without connection with the epidermis (Figure
1A). The features of malignancy include the
presence  of  frank  squamous  carcinomatous
changes, including high-grade cytological atyp-
ia, atypical mitoses, and focal tumor necrosis.
Although  the  number  of  cases  of  pilomatrix
carcinomas is very limited, these tumors can
be classified as malignant by applying the sim-
ple criteria of disregarding the pilomatrix fea-
tures  and  by  the  detection  of  obvious  squa-
mous cell carcinoma characteristics. Admixed
with the epithelial cells there were pigmented
dendritic  melanocytes  in  both  tumors,  high-
lighted  by  immunohistochemical  positivity
with melanocyte markers S-100 (Figure 1B),
Melan-A, and HMB45 (not shown). The tumors
were  composed  of  peripheral  basaloid  cells
admixed  with  larger  keratinocytes  and  focal
full  keratinization  admixed  with  pigmented
melanocytes,  and  formation  of  shadow  cells
with  loss  of  the  nucleus  (Figure  1C).  High-
grade cytological atypia was present and atyp  -
ical  mitoses  were  frequent  (Figure  1D).
Calcification  or  foreign  body  type  giant  cell
reaction was not present. Staining with E-cad-
herin (Figure 2A) and P-cadherin (Figure 2B)
showed a cell membrane distribution. In con-
trast  to  E-  and  P-cadherin,  b-catenin  was
expressed in the nucleus and cytoplasm of all
the tumor cells (Figures 2C and D), consistent
with a role as a transcriptional regulator rather
than a cell-cell adhesion protein. 
Discussion
Matrical tumors of the hair follicle consti-
tute a spectrum that includes those from the
common benign pilomatricomas to the excep-
tional melanocytic matricomas.
1-8 Melanocytic
matricomas  contain  dendritic  melanocytes
admixed with the epithelial tumor cells, and
the malignant variant called melanocytic pilo-
matrix carcinoma is the rarest of the group.
9
Hair  matrical  tumors  have  features  that
resemble  the  stages  of  hair  development.
During  the  development  of  the  hair  follicle,
primitive mesenchymal cells form the dermal
papilla and release soluble Wnt signals that
prevent  the  degradation  of  b-catenin  in
follicu  lar epithelial cells. Stable intracytoplas-
mic b-catenin translocates to the nucleus in
the inner hair matrix cells and acts as a tran-
scription factor activating Lef1 and down-reg-
ulating  the  cell-cell  adhesion  protein  E-cad-
herin. In contrast, b-catenin is distributed at
the cell membranes in the outer and inner fol-
Article
Figure 1. A, a routine hematoxylin and eosin (H&E) section from the tumor of patient 1,
showing a dermal nodule composed of peripheral basaloid cells with central squamous
differentiation (bar = 500 mm). B, S-100 staining demonstrating numerous dendritic
melanocytes admixed with the epithelial tumor cells (bar = 500 mm). C and D, routine
H&E sections showing melanin-pigmented cells (short arrows in C) admixed with the
epithelial tumor cells with ghost terminally differentiated squamous cells (long arrow in
C). There is marked epithelial cytological atypia and atypical mitoses (short arrows in D)
(bar = 125 mm). 
500 mm 500 mm
125 mm 125 mm
Figure 2. A, plasma membrane distribution of E-cadherin (bar = 50 µm) and B, P-cad-
herin (bar = 500 mm). The overlying epidermis serves as the internal positive control. In
contrast, b-catenin is in the nucleus and cytoplasm of all epithelial tumor cells (C and D).
Note the plasma membrane distribution of b-catenin in the epidermis in C, which serves
as the internal positive control. (Bar = 500 mm in C, and 50 mm in D.)
50 mm 500 mm
500 mm 50 mm
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licular root sheaths.
15 Therefore, b-catenin has
a dual role in hair development. It acts as a
transcription factor in matrix cells and is part
of the cadherin/catenin cell-cell adhesion com-
plex in the differentiated follicular cells, where
it is co-expressed with E (epithelial)-cadherin
and P (placental)-cadherin.
13,16,17 Mutation and
consequent aberrant transcriptional activation
of b-catenin and up-regulation of Wnt signals
was  demonstrated  in  benign  pilomatric  -
omas.
18,19 By immunohistochemistry, pilomatric  -
omas are seen to express nuclear b-catenin in
the basaloid and transitional cells.
20,21 In con-
trast, the fully differentiated shadow cells are
negative for b-catenin and are not under the
control  of  Wnt  signals.
22 Similarly  to  benign
pilomatricomas,  malignant  pilomatricomas
have  frequent  mutations  in  the  exon  3  of
CTNNB1, the gene encoding for b-catenin,
23
and  the  b-catenin  expression  can  be
decreased, probably reflecting low E-cadherin
21
as in other epithelial tumors with aggressive
behavior.  In  our  previous  work
24 we  showed
that  melanocytic  matricoma  exhibits  b-
catenin in the nucleus and cytoplasm of basal  -
oid cells. In contrast b-catenin was expressed
in the plasma membrane of the more differen-
tiated cells. In this paper we show that, in con-
trast to the plasma membrane distribution of
E- and P-cadherin, b-catenin is expressed dif-
fusely  in  the  nucleus  and  cytoplasm  of  all
tumor cells in two cases of melanocytic pilo-
matrix carcinoma. Comparative results of b-
catenin  mutation  and  immunohistochemical
distribution  in  benign  and  malignant  pilo -
matrix tumors are shown in Table 1. These
results are the first to show expression of cad-
herins and b-catenin in melanocytic piloma-
trix  carcinoma,  and  are  consistent  with  a
widespread  transcriptional  role  of  b-catenin
throughout the tumor cells.
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Table 1. List of reports and studies of benign and malignant variants of pilomatrical
tumors and their b-catenin mutations and immunohistochemical distribution. 
Hair matrical tumor b-catenin  Nuclear Source
mutations b-cat (IHC)
Pilomatricoma Frequent In basaloid cells Gat et al., 1998
18
Park et al., 2001
20
Hassanein and Glanz, 2004
21
Xia et al., 2006
19
Matricoma Not known Not known Ackerman et al., 1993
1
Melanocytic matricoma Not known In basaloid cells Peralta Soler et al., 2007
24
Pilomatrix carcinoma Frequent In basaloid cells Hassanein and Glanz, 2004
21
Lazar et al., 2005
23
Melanocytic pilomatrix carcinoma Not known In all cells This paper